First steps in the design of a system to monitor vaccine effectiveness during seasonal and pandemic influenza in EU/EEA Member States

Abstract

Binary file ES_Abstracts_Final_ECDC.txt matches

Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case–control study

“…In 2007, the European Centre for Disease Prevention and Control (ECDC) and a network of 18 public health institutes established the Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) project which monitors IVE each season in the EU and the European Economic Area (EEA) [2]. Currently 20 public health institutes from the EU and EEA are part of the I-MOVE network, which is coordinated by EpiConcept under the umbrella of ECDC [3].…”

Evaluation of inter-pandemic influenza vaccine effectiveness during eight consecutive winter seasons in England and Wales in patients with cardiovascular risk factors

“…Taken together, these phenomena increase the potential for under-powering of studies, as occurred in a number of winter seasons in the study, and thereby the potential for underestimation of vaccine effectiveness, which may well have also occurred. In contrast, alternative methodologies which use virologically confirmed influenza as the principle outcome continue to report vaccine effectiveness of around 60% [15,16]. Our study was confined to patients over 45 years of age with co-morbid conditions (mainly cardiovascular conditions) likely to have prompted previous consideration of prophylactic statin therapy; as such, the findings should not be generalised more widely.…”

“…This point is especially relevant in populations with underlying comorbidities. In the meantime, until the data from new studies are consolidated [15,16,18], elderly and high-risk people should continue to be vaccinated against influenza; even a vaccine with modest effectiveness may well contribute a large public health effect [19]. extracting and preparing the data; Douglas Fleming for facilitating access to the data and providing helpful comments and pointers; Puja Myles for further comments on the analysis; and all participating Weekly Returns Service GP practices for allowing use of their data.…”

Influenza vaccine for healthy adult workers: An issue for health authorities or employers?

“…The influenza vaccine efficacy (IVE) estimates for any one year can hardly be applied to the next one, because of the virus' seasonal mutability [11]. Since IVE mainly depends on the infectiousness of the virus and antigenic correspondence between the vaccine and the circulating strain -both of them hard to predict -the vaccine has maximal effectiveness if its content accurately predicts the virus type and circulation is high, i.e.…”